Skip to main content

Advertisement

Fig. 5 | Clinical and Translational Medicine

Fig. 5

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Fig. 5

Correlation between T790M relative mutation abundance (RMA) and osimertinib treatment outcomes. a Objective response rate (ORR) stratified by T790M RMA quartiles (P for trend = 0.063). b Progression-free survival (PFS) stratified by T790M RMA quartiles (P for trend = 0.043). c Receiver Operating Characteristic (ROC) Curve and area under ROC curve for T790M RMA predicting objective response. d ORR stratified by RMA-low and RMA-high patients (22.2% vs 63.6%, P = 0.006). e PFS stratified by RMA-low and RMA-high patients (P = 0.013, log-rank test)

Back to article page